By Kathleen Cameron, BSPharm, MPH | 11.19.2020
Key Takeaways:
·
There’s promising news in the
development of effective vaccines and treatments for the novel coronavirus, but
challenges remain.
·
The vaccine will be free, and the
Food & Drug Administration has created guidelines to ensure its safety.
·
The National Academies of Sciences
has developed a 4-phase framework for distributing the vaccine once it’s
approved.
The world recently received very encouraging news
from two of the many drug companies developing vaccines for the novel
coronavirus.
The two companies—Pfizer/BioNTech and
Moderna—reported much better than expected results from their large-scale
clinical studies, indicating 94-95% effectiveness in preventing illness. Both
vaccines prompt the body to produce a coronavirus protein and then mount an
immune response.
Preliminary results from Moderna’s and Pfizer’s
vaccine studies also indicate that individuals who received the vaccine and
developed COVID-19 did not get as sick as those who did not receive the vaccine
and contracted COVID. More promising news.
When will the
COVID-19 vaccine be available?
Both companies are anticipating that the vaccines
may be available as early as the end of the year through the Food & Drug
Administration (FDA) process of Emergency Use Authorization (EUA). This news is
truly light at the end of a long tunnel.
However, both vaccines have some challenges that
will need to be overcome with careful planning, adequate funding, and
coordination among the drug companies, government, and the health care
community. These include:
·
Two shots are needed to provide
protection. The second dose of Pfizer’s
vaccine must be administered 21 days after the first shot, and Moderna’s second
dose is administered 28 days after the first. The two vaccines are not
interchangeable. Education, tracking, and reminders will be key to ensuring
that everyone receives both doses.
·
Cold temperatures are required for
transportation and storage. Pfizer’s vaccine requires
temperatures of -70 degrees Celsius, colder than winter in Antarctica.
Fortunately, Pfizer has created its own packaging—nicknamed “the pizza box”—to
keep doses frozen without expensive special refrigerators, but only for 15
days. Moderna’s vaccine requires freezing, but more like regular refrigerator
temperatures.
·
How fast the companies can produce
the vaccine. Pfizer and Moderna have already
produced millions of doses, but not nearly enough to vaccinate even those at
high risk. The companies are ramping up efforts to manufacture more, but they
face challenges because the vaccines use new technology and the pandemic has
disrupted supply chains for many things from raw materials to glass vials.
Is the COVID-19
vaccine safe?
The FDA is requiring that companies only submit
EUA applications two months after the last dose. The FDA says this is enough
time to learn about side effects and adverse events from the vaccines. The
companies also will be required to collect data on adverse events long after
this two-month period. Common side effects are pain at the injection site,
fever, fatigue, and headache.
It’s still unclear how long the vaccines will provide
protection, and whether they will be needed every year similar to the flu
vaccine. For older adults, these questions are very important because as we
age, our immune systems weaken and the response to the vaccine may not be as
high as other age groups.
How much will the
vaccine cost?
In October, the federal government announced that
the COVID-19 vaccine will be free of charge for people with Medicare, Medicaid,
and private insurance, as well as for those with no insurance.
Who will get the
COVID-19 vaccine first?
The Centers for Disease Control (CDC) and states
will decide how to distribute the vaccines once they are approved and
available. We believe that the National Academies of Sciences, Engineering, and
Medicine’s framework for equitable distribution should serve as a guide. Their
plan includes four phases:
·
Phase 1 is for frontline health care workers in hospitals, nursing
homes, home care, and first responders. Also included are people of all ages
with multiple health conditions such as heart disease, diabetes, hypertension,
and obesity and those aged 65+ in congregate settings such as nursing homes.
·
Phase 2 includes K-12 teachers and school staff, child care workers,
and critical workers in high-risk settings such as grocery stores and public
transportation. Also included are all older adults not included in Phase 1 and
people of all ages with underlying conditions that put them at moderately
higher risk.
·
Phase 3 includes young adults, children, and workers in places like
colleges and universities, hotels, banks, exercise facilities, and factories
that pose moderately high risk of exposure.
·
Phase 4 covers everyone else residing in the U.S.
Are there
treatments for COVID-19?
The likelihood that a coronavirus infection will
prove fatal has dropped by nearly 30% since April due to improved treatments,
according to a new report from the University of Washington’s Institute for
Health Metrics and Evaluation.
Doctors have figured out better ways to care for
patients with COVID-19, including using blood thinners, oxygen support, and
remdesivir and the steroid dexamethasone for certain patients. In addition, the
FDA granted EUA for Eli Lilly’s antibody treatment for mild to moderate
COVID-19 for people with a positive test who are at high risk for progressing to
severe COVID-19.
Can we return to
normal activities now that a vaccine is on the horizon?
We all are eager to get back to normal life.
While this vaccine news is promising, it will still take some time to reach
most of the population. That means we must continue to adhere to the very
important safety precautions issued by the CDC, states, and localities. Always
remember to protect yourself and those around you by:
·
Wearing a face mask at all times in
public and when around people not in your household
·
Keeping 6 feet apart from people not
in your household
·
Washing hands frequently
·
Avoiding crowds
About Kathleen Cameron, BSPharm, MPH
Kathleen Cameron is Senior Director of NCOA's Center for Healthy
Aging. Kathy has more than 25 years of experience in the health care field as a
pharmacist, researcher, and program director focusing on falls prevention,
geriatric pharmacotherapy, mental health, long-term services and supports, and
caregiving.
This comment has been removed by a blog administrator.
ReplyDelete